8 minute read
Apr. 25, 2024
TNG462: Selective Targeting of the PRMT5:MTA Complex for MTAP-Deleted Cancers
TNG462
oral, MTA-cooperative PRMT5 inhibitor Ph. I for MTAP-deleted solid tumors optimized HTS hit ACS Fall 2023 meeting presentation Tango Therapeutics, Boston, MA
Loading...
